Please wait while the formulary information is being retrieved.
VIDAZA (AZACITIDINE)
- Myelodysplastic syndrome
100 mg solution for injection
- Inject 75 mg/m2 by subcutaneous route once daily for 7 days
100 mg solution for injection
- Inject 75 mg/m2 by subcutaneous route once daily for 7 days
Myelodysplastic syndrome
- Inject 75 mg/m2 by subcutaneous route once daily for 7 days
- Inject 75 mg/m2 by subcutaneous route once daily for 7 days of a 28 day treatment cycle for doses >100 mg/4 ml, divide into 2 injections, inject into 2 separate sites rotate among thigh, abdomen and upper arm at least 1 inch from old site
- Inject 100 mg/m2 by subcutaneous route once daily for 7 days of a 28 day treatment cycle for doses >100 mg/4 ml, divide into 2 injections, inject into 2 separate sites rotate among thigh, abdomen and upper armat least 1 inch from old site
- Inject 37.5 mg/m2 by subcutaneous route once daily for 7 days of a 28Day treatment cycle
- Inject 24.75 mg/m2 by subcutaneous route once daily for 7 days of a 28 day treatment cycle
- Infuse 37.5 mg/m2 over 10-40 minute(s) by intravenous route once daily for 7 days of a 28 day treatment cycle
- Infuse 24.75 mg/m2 over 10-40 minute(s) by intravenous route once daily for 7 days of a 28 day treatment cycle
- Infuse 75 mg/m2 over 10-40 minute(s) by intravenous route once daily for 7 days of a 28 day treatment cycle
- Infuse 100 mg/m2 over 10-40 minute(s) by intravenous route once dailyfor 7 days of a 28 day treatment cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Advanced malignant neoplasm of liver
- Lactating mother
Contraindicated
- Kidney disease with reduction in GFR
- Pregnancy
- Severe hepatic disease
Severe
Moderate
- Neutropenic disorder
- Thrombocytopenic disorder
VIDAZA (AZACITIDINE)
- Myelodysplastic syndrome
- Anaphylaxis
- Anemia
- Cellulitis
- Chest pain
- Dyspnea
- Leukopenia
- Neutropenic disorder
- Pharyngitis
- Pneumonia
- Thrombocytopenic disorder
- Upper respiratory infection
- Urinary tract infection
- Acute abdominal pain
- Anorexia
- Arthralgias
- Bruising
- Chills
- Constipation
- Diarrhea
- Dizziness
- Dry skin
- Dyspepsia
- Ecchymosis
- Erythema
- Fatigue
- Fever
- General weakness
- Generalized abdominal tenderness
- Gingival bleeding
- Headache disorder
- Hematoma
- Injection site sequelae
- Insomnia
- Lethargy
- Loose stools
- Malaise
- Myalgias
- Nausea
- Petechiae
- Pruritus of skin
- Skin nodules
- Skin rash
- Stomatitis
- Symptoms of anxiety
- Urticaria
- Vomiting
- Weight loss
More Frequent
Severe
Less Severe
- Oral hemorrhage
- Hypotension
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory distress syndrome
- Agranulocytosis
- Bacterial sepsis
- Black tarry stools
- Chemotherapy-induced hyperuricemia
- Cholecystitis
- Dermal necrosis
- Diverticulitis of gastrointestinal tract
- Gastrointestinal hemorrhage
- Hemoptysis
- Hepatic coma
- Hypokalemia
- Interstitial lung disease
- Intracerebral hemorrhage
- Kidney disease with reduction in GFR
- Muscle weakness
- Necrotizing fasciitis
- Ocular hemorrhage
- Orthostatic hypotension
- Pancytopenia
- Pyoderma gangrenosum
- Renal failure
- Renal tubular acidosis
- Seizure disorder
- Sweet's syndrome
Less Severe
- Bone pain
- Induration of skin
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Azacitidine
Rare myelodysplastic syndrome in children often differs from adult subtypes. Safety and efficacy not established.
- 1 Day – 18 Years
- Rare myelodysplastic syndrome in children often differs from adult subtypes. Safety and efficacy not established.
Azacitidine
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Azacitidine
Avoid during tx and for 1 week after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Avoid during tx and for 1 week after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Azacitidine
Renal-Monitor renal function in elderly since they have a higher incidence of drug induced renal dysfunction.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Myelodysplastic syndrome | |
| D46 | Myelodysplastic syndromes |
| D46.0 | Refractory anemia without ring sideroblasts, so stated |
| D46.1 | Refractory anemia with ring sideroblasts |
| D46.2 | Refractory anemia with excess of blasts [RAEb] |
| D46.20 | Refractory anemia with excess of blasts, unspecified |
| D46.21 | Refractory anemia with excess of blasts 1 |
| D46.22 | Refractory anemia with excess of blasts 2 |
| D46.4 | Refractory anemia, unspecified |
| D46.9 | Myelodysplastic syndrome, unspecified |
| D46.A | Refractory cytopenia with multilineage dysplasia |
| D46.B | Refractory cytopenia with multilineage dysplasia and ring sideroblasts |
| D46.C | Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality |
| D46.Z | Other myelodysplastic syndromes |
| 0-9 | A-Z |
|---|---|
| D46 | Myelodysplastic syndromes |
| D46.0 | Refractory anemia without ring sideroblasts, so stated |
| D46.1 | Refractory anemia with ring sideroblasts |
| D46.2 | Refractory anemia with excess of blasts [RAEb] |
| D46.20 | Refractory anemia with excess of blasts, unspecified |
| D46.21 | Refractory anemia with excess of blasts 1 |
| D46.22 | Refractory anemia with excess of blasts 2 |
| D46.4 | Refractory anemia, unspecified |
| D46.9 | Myelodysplastic syndrome, unspecified |
| D46.A | Refractory cytopenia with multilineage dysplasia |
| D46.B | Refractory cytopenia with multilineage dysplasia and ring sideroblasts |
| D46.C | Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality |
| D46.Z | Other myelodysplastic syndromes |
Formulary Reference Tool